Evidence map›Paper›PMID 34512662›Full record

ArticleFrontiers in immunology2021

The Dual Targeting of FcRn and FcγRs

Céline Monnet, Emilie Jacque, Christophe de Romeuf, Alexandre Fontayne, Toufik Abache, Nathalie Fournier, Gilles Dupont, Delphine Derache, Anais Engrand, Aurélie Bauduin and 16 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. The therapeutic age of the neonatal Fc receptor.Nature reviews. Immunology · 2023
    Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 2 countries.

Céline MonnetLFB Biotechnologies, Innovation Department, Les Ulis, France.
Emilie JacqueLFB Biotechnologies, Innovation Department, Les Ulis, France.
Christophe de RomeufLFB Biotechnologies, Innovation Department, Les Ulis, France.
Alexandre FontayneLFB Biotechnologies, Innovation Department, Les Ulis, France.
Toufik AbacheLFB Biotechnologies, Innovation Department, Les Ulis, France.
Nathalie FournierLFB Biotechnologies, Innovation Department, Les Ulis, France.
Gilles DupontLFB Biotechnologies, Innovation Department, Les Ulis, France.
Delphine DeracheLFB Biotechnologies, Innovation Department, Les Ulis, France.
Anais EngrandLFB Biotechnologies, Innovation Department, Les Ulis, France.
Aurélie BauduinLFB Biotechnologies, Innovation Department, Les Ulis, France.
Aurélie TerrierLFB Biotechnologies, Innovation Department, Les Ulis, France.
Alexander SeifertLFB Biotechnologies, Innovation Department, Les Ulis, France.
Cécile BeghinLFB Biotechnologies, Innovation Department, Les Ulis, France.
Alain LongueLFB Biotechnologies, Innovation Department, Les Ulis, France.
Nicholas MasielloLFB Biotechnologies, Innovation Department, Les Ulis, France.
Laetitia DaninoLFB Biotechnologies, Innovation Department, Les Ulis, France.
Michel NogreLFB Biotechnologies, Innovation Department, Les Ulis, France.
Anais RaiaLFB Biotechnologies, Innovation Department, Les Ulis, France.
Frederic DhainautLFB Biotechnologies, Innovation Department, Les Ulis, France.
Louis FauconnierArtimmune, Orléans, France.
Dieudonnée TogbeArtimmune, Orléans, France.
Carmen ReitingerDivision of Genetics, Department of Biology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Falk NimmerjahnDivision of Genetics, Department of Biology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Wil StevensLFB Biotechnologies, Innovation Department, Les Ulis, France.
Sami ChtourouLFB Biotechnologies, Innovation Department, Les Ulis, France.
Philippe MondonLFB Biotechnologies, Innovation Department, Les Ulis, France.
LFB (France) · FRFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversité d'Orléans · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel molecules that directly target the neonatal Fc receptor (FcRn) and/or Fc gamma receptors (FcγRs) are emerging as promising treatments for immunoglobulin G (IgG)-dependent autoimmune pathologies. Mutated Fc regions and monoclonal antibodies that target FcRn are currently in clinical development and hold promise for reducing the levels of circulating IgG. Additionally, engineered structures containing multimeric Fc regions allow the dual targeting of FcRn and FcγRs; however, their tolerance needs to first be validated in phase I clinical studies. Here, for the first time, we have developed a modified monomeric recombinant Fc optimized for binding to all FcRns and FcγRs without the drawback of possible tolerance associated with FcγR cross-linking. A rational approach using Fc engineering allowed the selection of LFBD192, an Fc with a combination of six mutations that exhibits improved binding to human FcRn and FcγR as well as mouse FcRn and FcγRIV. The potency of LFBD192 was compared with that of intravenous immunoglobulin (IVIg), an FcRn blocker (Fc-MST-HN), and a trimeric Fc that blocks FcRn and/or immune complex-mediated cell activation through FcγR without triggering an immune reaction in several

Indexed as

AnimalsAntirheumatic AgentsArthritis, ExperimentalAutoimmunityBinding, CompetitiveComplement C5aFemaleHistocompatibility Antigens Class IHumansImmunoglobulin Fc FragmentsInterleukin-2Jurkat CellsKineticsMiceMice, Inbred C57BLMice, TransgenicAntirheumatic AgentsComplement C5aFc receptor, neonatalHistocompatibility Antigens Class IIL2 protein, humanImmunoglobulin Fc FragmentsInterleukin-2Receptors, FcReceptors, IgGautoantibodiesautoimmune diseaseFc engineeringFc fragmentFc gamma receptor (FcγR)FcRnimmune complex (IC)

Identifiers

PMID34512662
PMCPMC8427755
OpenAlexW3197847933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.